Patents by Inventor Peter J. Scammells

Peter J. Scammells has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
    Patent number: 7019027
    Abstract: The present invention relates to a compound of formula (I): wherein: R3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and R4 and R5 taken together form a ring having from 5 to 10 carbon atoms. Additionally, the invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal subject, such as a human, wherein increased angiogenesis is desired, comprising administering to a mammal in need of such therapy an effective amount of the aforementioned thiophene selective adenosine A1 allosteric enhancer.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: March 28, 2006
    Inventors: Joel M. Linden, Ray A. Ollson, Peter J. Scammells
  • 2-Amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
    Publication number: 20040180948
    Abstract: The present invention relates to a compound of formula (I): 1
    Type: Application
    Filed: March 23, 2004
    Publication date: September 16, 2004
    Inventors: Joel M. Linden, Ray A. Ollson, Peter J. Scammells
  • 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
    Patent number: 6713638
    Abstract: The present invention relates to a compound of formula (I): wherein: R3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and R4 and R5 taken together form a ring having from 5 to 10 carbon atoms. Additionally, the invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal subject, such as a human, wherein increased angiogenesis is desired, comprising administering to a mammal in need of such therapy an effective amount of the aforementioned thiophene selective adenosine A1 allosteric enhancer.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: March 30, 2004
    Inventors: Joel M. Linden, Ray A. Ollson, Peter J. Scammells
  • 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
    Publication number: 20030078248
    Abstract: The present invention relates to a compound of formula (I): 1
    Type: Application
    Filed: May 20, 2002
    Publication date: April 24, 2003
    Inventors: Joel M. Linden, Ray A. Ollson, Peter J. Scammells
  • Method for using A.sub.1 adenosine receptor agonists
    Patent number: 5998387
    Abstract: Adenosine and xanthine deriviatives, and compositions comprising those compounds, are potent selective agonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias.
    Type: Grant
    Filed: April 6, 1998
    Date of Patent: December 7, 1999
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Luiz Belardinelli, Ray Olsson, Stephen Baker, Peter J. Scammells, Peter G. Milner, Jurg R. Pfister
  • N.sup.6 -(epoxynorborn-2-yl) adenosines as A.sub.1 adenosine receptor agonists
    Patent number: 5736528
    Abstract: N.sup.6 -(epoxynorborn-2-yl)adenosines are Al adenosine receptor agonists that are useful for controlling atrial fibrillation, ventricular rate in atrial flutter, supraventricular tachyarrhythmia, inhibiting A--V- nodal transmission in supraventricular tachycardia, and for normalizing ventricular rhythm and hemodynamics.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: April 7, 1998
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Luiz Belardinelli, Ray Olsson, Stephen Baker, Peter J. Scammells, Peter G. Milner, Jurg R. Pfister
  • A1 adenosine receptor agonists and antagonists
    Patent number: 5668139
    Abstract: Adenosine and xanthine derivatives, and compositions comprising those compounds, are potent selective agonists and antagonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 16, 1997
    Assignee: University of Flordia Research Foundation, Inc.
    Inventors: Luiz Belardinelli, Ray Olsson, Stephen Baker, Peter J. Scammells, Peter G. Milner, Jurg R. Pfister, George F. Schreiner
  • Xanthine epoxides as A.sub.1 adenosine receptor agonists and antagonists
    Patent number: 5631260
    Abstract: Xanthine derivatives, and compositions comprising those compounds, are potent selective antagonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias. The compounds, specifically, are C-8 epoxide derivatives of xanthine having the general formulae of: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different, and can be H or an alkyl group of 1-4 carbons, and n=0-4; and ##STR2## wherein R.sub.1 and R.sub.2 are the same or different, and can be H or an alkyl group of 1-4 carbons, R.sub.3 is either O or (CH.sub.2).sub.1-4, and n=0-4.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: May 20, 1997
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Luiz Belardinelli, Ray Olsson, Stephen Baker, Peter J. Scammells, Peter G. Milner, J urg R. Pfister, George F. Schreiner
  • A1 adenosine receptor agonists and antagonists as diuretics
    Patent number: 5446046
    Abstract: Adenosine and xanthine derivatives, and compositions comprising those compounds, are potent selective agonists and antagonists of adenosine receptors. The derivatives and composition are used to treat conditions, including certain cardiac arrhythmias.
    Type: Grant
    Filed: October 28, 1993
    Date of Patent: August 29, 1995
    Assignee: University of Florida Research Foundation
    Inventors: Luiz Belardinelli, Ray Olsson, Stephen Baker, Peter J. Scammells
  • Pyrazolo[3,4-d]pyrimidines with adenosine-like binding affinities
    Patent number: 5227485
    Abstract: The A21 receptor extracelluar site and the A2 receptor extracellular site of adenosine analogues are structurally different and that binding orientations of adenosine or adenosine analogues are different at these sites and this may be used to determine their structure. Novel pyrimidine compounds are described.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: July 13, 1993
    Assignee: Griffith University
    Inventors: Ronald J. Quinn, Michael J. Dooley, Peter J. Scammells, Mary Chebib